Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2008
10/21/2008US7439228 Bioactive peptides
10/21/2008US7439224 Indications of mannan-binding lectin (MBL) in the treatment of immuno-compromised individuals
10/21/2008US7439059 Compositions and methods for activating genes of interest
10/21/2008US7438922 Allogeneic immunotherapy agent for cancer therapy; vaccine
10/21/2008US7438911 Antibody against human insulin-like growth factor
10/21/2008US7438908 Antitumor agents
10/21/2008US7438890 Binding peptides for carcinoembryonic antigen (CEA)
10/21/2008CA2387383C Use of anti-ferritin monoclonal antibodies in the treatment of some cancers
10/21/2008CA2351947C Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
10/21/2008CA2336624C Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
10/21/2008CA2301401C Determining the transforming capability of agents
10/21/2008CA2296012C Epothilone derivatives
10/21/2008CA2270893C N-aryl substituted tetrahydroquinolines ligands for retinoid receptors having agonist, antagonist or inverse agonist type activity
10/21/2008CA2230452C Novel 3' terminal sequence of hepatitis c virus genome and diagnostic and therapeutic uses thereof
10/21/2008CA2146707C Substituted n-heteroaroylguanidines as inhibitors of na+/h+ exchange
10/21/2008CA2042064C C-erbb-2 external domain:gp75
10/16/2008WO2008124735A2 Multi-functional polyglutamate drug carriers
10/16/2008WO2008124703A2 Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry
10/16/2008WO2008124699A1 A method of using proteasome inhibitors in combination with histone deacetylase inhibitors to treat cancer
10/16/2008WO2008124681A2 Methods and systems for treating cell proliferation disorders
10/16/2008WO2008124614A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
10/16/2008WO2008124610A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
10/16/2008WO2008124524A2 Aryl sulfonamide compounds as modulators of the cck2 receptor
10/16/2008WO2008124393A1 Benzothiazole derivatives and their use as protein kinase inhibitors
10/16/2008WO2008124323A1 Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
10/16/2008WO2008124161A1 Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
10/16/2008WO2008124145A1 Steroid compounds, compositions, and methods of treatment
10/16/2008WO2008124125A1 Anti-tumor activity of temsirolimus in papillary renal cell cancer
10/16/2008WO2008124097A2 Salts of isophosphoramide mustard and analogs thereof
10/16/2008WO2008124085A2 Methods of using combinations of mek and jak-2 inhibitors
10/16/2008WO2008124083A2 Aurora kinase modulators and method of use
10/16/2008WO2008124026A1 Wortmannin-rapamycin conjugate and uses thereof
10/16/2008WO2008124020A1 Wortmannin-rapalog conjugate and uses thereof
10/16/2008WO2008123891A1 PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
10/16/2008WO2008123298A1 Infusion preparation for cancer patient
10/16/2008WO2008123231A1 Novel cyclic staple-type oligonucleotide, and nf-κb decoy comprising the same
10/16/2008WO2008123202A1 METHOD FOR INHIBITION OF SIGNALING THROUGH ErbB2, SIGNALING INHIBITOR FOR USE IN THE METHOD, AND USE OF THE SIGNALING INHIBITOR
10/16/2008WO2008122798A2 Pharmaceutical composition of an eg5 inhibitor and a microtubule interfering agent for the treatment of cancer
10/16/2008WO2008122779A1 Combination of a purine-based cdk inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders
10/16/2008WO2008122767A2 2, 6, 9-substituted purine derivatives having anti proliferative properties
10/16/2008WO2008122667A2 Ureylene derivatives
10/16/2008WO2008122615A1 [2, 6] naphthyridines useful as protein kinase inhibitors
10/16/2008WO2008122551A2 Anti-epcam antibody and uses thereof
10/16/2008WO2008122198A1 Non-steroidal androgen acceptor regulators and their medical use
10/16/2008WO2008106479A3 Poly(1,4-piperazin-2-ones) as rod-like protein- protein interaction inhibitors and their production
10/16/2008WO2008096268A3 Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
10/16/2008WO2008086122A3 Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
10/16/2008WO2008079988A3 Quinazolines for pdk1 inhibition
10/16/2008WO2008070586A3 Compositions and methods for treatment of protein misfolding and protein aggregation diseases
10/16/2008WO2008058547A3 Alpha-lactalbumin composition
10/16/2008WO2008058125A3 Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs
10/16/2008WO2008046407A3 Use of deuterium dioxide for treating hyperproliferative skin diseases
10/16/2008WO2008014296A3 Composition and method for treatment of tumors
10/16/2008WO2007134595A3 Novel formulation, oriented to tumour physiology, of a cytostatic, in particular of cis-platinum
10/16/2008WO2007115289A8 Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
10/16/2008WO2007105058A8 Pyrazole compounds
10/16/2008WO2007002720A8 An impurity of anastrozole intermediate, and uses thereof
10/16/2008US20080255248 Coupling a stabilizing group-oligopeptide conjugate with the free therapeutic agent, binding with a polymeric resin forming a therapeutic agent-polymeric resin complex; high specificity of action, a reduced toxicity, an improved stability in the serum and blood
10/16/2008US20080255244 CaM Kinase II Inhibitor Improves Retinoic Acid Therapy and Inhibits the Proliferation of Myeloid Leukemia Cells
10/16/2008US20080255243 Stat3 as a theranostic indicator
10/16/2008US20080255240 Obesity; dietetics; hypotensive agents; antidiabetic agents; dyslipidemia; cardiovascular disorders; osteoarthritis; gall bladder disease; endometrosis; anticancer agents; vascular system disorders; apoptosis
10/16/2008US20080255222 Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
10/16/2008US20080255221 Novel hydroxamates as therapeutic agents
10/16/2008US20080255214 Novel hydroxamates as therapeutic agents
10/16/2008US20080255213 4R)-2-(benzo[d][1,3]dioxol-5-yl)-N-decylthiazolidine-4-carboxamide; prostate cancer, breast cancer, ovarian cancer, skin cancer
10/16/2008US20080255211 cannabinoid receptors modulators; metabolic syndrome, obesity, hyperlipidemia, type II diabetes, atherosclerosis, substance addiction, liver cirrhosis, schizophrenia, sexual dysfunction, anxiety; 5-(5-(5-bromoselenophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-3-tert-butyl-1,2,4-oxadiazole
10/16/2008US20080255191 Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
10/16/2008US20080255184 N-[3-(4-amino-7-pyridin-3-ylthieno[3,2-c]pyridin-3-yl)phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea; lymphoma, melanoma, small cell lung , non-small cell lung, breast, colon and pancreatic cancer
10/16/2008US20080255183 N-[(3,5-dimethylisoxazol-4-yl)carbonyl]-3-{5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]thiophen-2-yl}-L-alanine; treatment of solid tumors
10/16/2008US20080255182 Certain chemical entities, compositions, and methods
10/16/2008US20080255177 Rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid; mTOR inhibitor
10/16/2008US20080255175 4-Ethyl-4-(1,4-dioxo-3-azahept-5-enoxy-),9-desamino-camptothecin where the 9-amino may be present as dimethylamino with an alkyl sulfo group on carbon #8; Camptothecin derivatives having greater biological activity/enhanced stability, topoisomerase I inhibitors; side effect reductions; antitumor agents
10/16/2008US20080255171 Combination of Nilotinib with Farnesyl Transferase Inhibitors
10/16/2008US20080255169 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread
10/16/2008US20080255165 Pharmaceutical Compositions of the Isolated D-Enantiomer of the Quinazolinone Derivative Halofuginone
10/16/2008US20080255163 Compounds such as 2-piperidino-6-methyl-5-oxo-5,6-dihydro-(7H) pyrrole-[3,4-d]pyrimidine maleate (MS-818); nervous system, brain, and neurodegenerative disorders; Parkinson's, Alzheimer's, and Huntington's disease
10/16/2008US20080255162 Treating diseases mediated by phosphatidyl inositol 3-kinase; cardiovascular disorders; anticarcinogenic, antiarthritic, anticoagulant, antiinflammatory, antiischemic,and hypotensive agents; chronic obstructive pulmonary disease; autoimmune diseases; diabetes, atherosclerosis, bronchitis, strokes
10/16/2008US20080255160 Mapk/erk kinase inhibitors
10/16/2008US20080255157 Promoting microtube polymerization; drug resistant cancer; 5-Azepan-1-yl-7-chloro-6-(2,4,6-trifluorophenyl)imidazo[1,2-a]pyrimidine
10/16/2008US20080255155 Inhibit protein tyrosine kinase; treating cell proliferative diseases and conditions; N-(6-(2-Fluoro-4-(4,4,4-trifluoro-3-(4-fluorophenylamino)butanamido)phenoxy)pyrimidin-4-yl)pyrrolidine-1-carboxamide
10/16/2008US20080255149 1-Oxopiperidine derivatives; amides derived from fused and/or spiro polyheterocycles such as decahydro-(iso)quinoline, tetrahydro(iso)quinoline, piperazine, piperidine, indole, or (iso)indole; histone deacetylase inhibitors; antiproliferative, antitumor, and antitumor agents; hyperplasia; immune diseases
10/16/2008US20080255146 Macrolide compounds comprising 18,19-epoxytricosa-8,12,14-trien-11-olide derivatives; angiogenesis inhibitors; anticarcinogenic, antimetastasis, antiinflammatory, and antitumor agents; antihypoxic agents; endothelial growth factor suppressors; retinal neovascularization, diabetic retinopathy
10/16/2008US20080255143 Inhibitors of Akt Activity
10/16/2008US20080255141 Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders
10/16/2008US20080255140 2-(N'-2-amino-3,4-dioxocyclobutenyl)-N-piperazinyl)-pyrimidine-5-hydroxamic acid derivatives; antiproliferative, anticarcinogenic, and antitumor agents; psoriasis; skin, respiratory system, psychological, and genetic disorders; transplant rejection; Alzheimer's and Parkinson's disease; vision defects
10/16/2008US20080255139 Use Of 4- (4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3-(4-(Pyridin-3-Yl)Pyrimidin-2-Ylamino)Phenyl]-Benzamide to Inhibit the Tyrosine Kinase Receptor C-Fms
10/16/2008US20080255133 N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents
10/16/2008US20080255132 Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
10/16/2008US20080255129 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics
10/16/2008US20080255128 e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis
10/16/2008US20080255126 Inhibitors of post-proline cleaving proteases
10/16/2008US20080255124 4-[(Cyclopropylmethyl)(2-{[4-(1,1-dimethylethyl)phenyl]oxy}ethyl)amino]-2-(trifluoromethyl)benzonitrile; modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors; osteoporosis, muscle wasting,endometriosis, cardiovascular disease; breast, uterine cancer, prostatic hyperplasia
10/16/2008US20080255120 Substituted 2,5-heterocyclic derivatives
10/16/2008US20080255119 e.g. 5-[rac-cis-2,3-Bis-(4-chloro-phenyl)-5-oxo-2,3-dihydro-5H-imidazo[1,2-a]pyridine-1-sulfonyl]-2-fluoro-benzonitrile; inhibit the interaction of tumor suppressor MDM2 protein with a p53-like peptide; antiproliferative agent; cycle arrest in G1 and G2 phase
10/16/2008US20080255115 (5Z)-5-{[4-(4-pyridinyl)-6-quinolinyl]methylidene}-1,3-thiazolidine-2,4-dione; autoimmune disorders, inflammatory, cardiovascular, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection
10/16/2008US20080255110 Imidazoquinoline derivatives as adenosine a3 receptor ligands
10/16/2008US20080255109 Antigonadotrophins; breast and prostate cancer, endometriosis, benign prostate hyperplasia; regulation of fertility; 4-(3-Chloro-4-{{(4-chloro-benzenesulfonyl)-methyl-amino]-methyl}-thiophene-2-carbonyl)-3,4-dihydro-2H-benzo[1,4]oxazine-2carboxylic acid (3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-amide
10/16/2008US20080255090 Ceratamines A and B, and Analogues, Syntheses and Pharmaceutical Compositions Thereof
10/16/2008US20080255087 Use of indolocarbazole antibiotic K252a derivatives as ERK inhibitors; amidation of K252a derivatives
10/16/2008US20080255080 Hydroquinone Ansamycin Formulations
1 ... 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 ... 2211